FDA approves 6-price vaccine Vaxelis for 6-week-old son to 4-year-old

recently, Sanofi announced that the U.SFood andMedicines(http://Administration (
FDA(http://) has approved vaxelis, a liquid-all-liquid, ready-to-use six-in-one vaccine for children between 6 weeks of age and 4 years of age (before their 5th birthday)VaxelisVaxelis is an active immune vaccine for infants between 6 weeks of age and age 4 years old to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and invasive diseases caused by Haemophilus influenzae type BVaxelis uses a 3-pin immune procedure to give muscle injections at 2, 4 and 6 months of age at a dose of 0.5mLVaxelis is part of Sanofi's strategic partnership with Mercado, which is working to maximize Vaxelis production to achieve a sustainable vaccine supply
(http://to meet the expected U.Smarket demandVaxelis will be fully commercialized in the U.S market no earlier than 2020, according to a statement released by Sanofi In the European Union, Vaxelis was approved in May 2016 to prevent six different diseases for infants and young children older than 6 weeks of age note
note is noteworthy that Vaxelis is prohibited from having a history of severe allergic reactions to previously immunized Vaxelis, Vaxelis, any components or any other diphtheria toxin, tetanus toxoid, pertussis-containing vaccine, inactivated polio vaccine, hepatitis B vaccine or influenza B vaccine in addition, the vaccine cannot be used within 7 days of vaccination with a history of mental health (e.g coma, low level of consciousness, long-term seizures) or whooping cough In addition, Vaxelis should not be administered to children with a history of sexual lymonal disorders until a treatment plan is determined and the condition is stabilized